The Innovation System Behind Moderna’s Covid-19 Vaccine
HBR IdeaCast
Noubar Afeyan, cofounder and chair of Moderna Therapeutics and CEO of Flagship Pioneering, says that the breakthrough innovation behind the company’s Covid-19 vaccine came not as a stroke of luck, but from a repeatable process. He outlines a system called “emergent discovery” that involves working back from future ideals, pioneering in novel spaces, encouraging unreasonable ideas, and persistently questioning hypotheses. And he says this process applies to other industries besides life sciences. Afeyan is the coauthor, with HBS professor Gary Pisano, of the HBR article "What Evolution Can Teach Us About Innovation."Next Episodes
Can Big Tech Reform Itself? @ HBR IdeaCast
📆 2021-09-14 16:00 / ⌛ 00:26:54
Why Companies Need Returnship Programs (Back to Work, Better) @ HBR IdeaCast
📆 2021-09-07 16:00 / ⌛ 00:20:37
How the Pandemic Changed Talent Management (Back to Work, Better) @ HBR IdeaCast
📆 2021-08-31 16:00 / ⌛ 00:29:25
Best of IdeaCast: Saying No to More Work @ HBR IdeaCast
📆 2021-08-26 18:22 / ⌛ 00:21:46
What We Still Need to Learn about AI in Marketing — and Beyond @ HBR IdeaCast
📆 2021-08-24 16:00 / ⌛ 00:22:33